Page 1 | Search Results | Blood Advances | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

It is feasible and safe to stop specialized follow-up of asymptomatic lower risk chronic lymphocytic leukemia

Christian Brieghel, Caspar da Cunha-Bang, Jindrich Mourek, Lars Kjeldsen, Carsten Utoft Niemann

Blood Adv bloodadvances.2023012382.

https://doi.org/10.1182/bloodadvances.2023012382

Published: 2024

Includes: Supplemental data

Journal Articles

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial

Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Jon Riise, Sirpa Leppä, Jacob Haaber Christensen, Kristina Sonnevi, Lone Bredo Pedersen, Karin Fahl Wader, Ingrid Glimelius

Blood Adv (2024) 8 (2): 407–415.

https://doi.org/10.1182/bloodadvances.2023011920

Published: 2024

Includes: Supplemental data

Journal Articles

Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations

Matilde Slot, Carsten Utoft Niemann, Lars Holger Ehlers, Emelie Curovic Rotbain

Blood Adv (2023) 7 (15): 4186–4196.

https://doi.org/10.1182/bloodadvances.2023010108

Published: 2023

Includes: Supplemental data